special edition episode is brought to you by the AmerisourceBergen Insights
podcast. In Part 1 of this two-part series on insulin biosimilars, host
Jennifer Kemper, Director of Content Strategy, speaks with Sean McGowan, Senior
Director of Biosimilars, Michelle Jesse, Director of Biosimilar
Commercialization, and Brad Tallamy, Senior Director of Government Affairs,
about what these new drugs could mean for the category. They’ll discuss how and
why insulins are in the biosimilar category, how congress is approaching
biosimilars, and if an interchangeability status is on the horizon.